Panavir from Russia – alternative treatment for HPV and genital warts

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Biologically active substance of Panavir is ”GG17” – plant polysaccharide from Solanum tuberosum. GG17 is a high-molecular hexose glycoside with complex structure: Glucose (38,5%), Galactose (14,5%), Rhamnose (9%), Mannose (2,5%), Xylose (1,5%), Uronic acid (3,5%).

Preparation was developed by the company National Research Company jointly with Research Institute of Physicochemical Medicine, Ministry of Health and Social Development of the Russian Federation, under the direction of the academician of RAMS Sergienko V.I.


This research is devoted to determination of the clinical efficacy of Panavir in the combined therapy of the uterine cervix diseases associated with human papillomavirus (HPV). The article presents data of the complex examination of 59 patients. Patients with diagnosed 16th, 18th, 31st, 33rd types of HPV underwent destructive methods of treatment of the cervix followed by Panavir. The efficacy of Panavir was estimated by PCR in 3, 6 and 12 months from the beginning of treatment and it was 84,7%. Antiviral therapy permits to prevent recurrence of papillomavirus infection of the cervix uteri.


All the patients were given Panavir rectal suppositories in a daily dose of 200 mg for 10 days. Radio waves were used to destroy anogenital warts in Group 1 patients. The patients were examined using laboratory monitoring immediately and 30, 60, and 90 days after therapy. Results. Following 3 months of Panavir therapy in combination with radio wave mass destruction, human papillomavirus DNA was not detected in 80% of the patients; remission was recorded in 90%. After 3 months of Panavir use, 85% of the patients with latent infection were found to cease human papillomavirus DNA excretion. Conclusion. The high clinical efficacy of Panavir suppositories permits one to recommend the agent in this formulation for wide practical application.



The article presents the results of treatment of 51 men with recurrent genital HPV infection in the form of genital warts. Patients were divided into two groups depending on the treatment. Group 1 of patients has received the combination treatment–electrocoagulation + pharmacotherapy (panavir intravenously and topically in the form of a gel), Group 2 of patients–only electrocoagulation. According to the results of follow-up within 6 months, disease recurrence rate was significantly higher in Group 2–39.5% versus 9.6% in the Group 1. Postoperative complications were also more frequently recorded in the Group 2. These findings suggest that the combined treatment of reccurent forms of genital warts is preferred than just using destructive methods of treatment.


The efficiency of combined therapy in patients with HPV-associated chronic endocervitis was investigated. The antiviral preparation modulating immune response (panavir) was used. The results showed that panavir increases the efficiency of therapy and eliminates the HPV in 96,6% of patients.



The results of combination therapy were comparatively analyzed in 60 patients with human papillomavirus (HPV)-associated cervical neoplasias. Thirty patients in the study group were given the antiviral and immunomodulatory drug – intravenous and intravaginal panavir before destructive treatment. Thirty patients in the control group had traditional destructive treatment. It has been ascertained that the use of systemic and local combination antiviral therapy before destructive treatments enhances the efficiency of the therapy performed, promotes a reduction in process relapsing, and leads to HPV elimination in 85% of cases.


I found informations about Panavir when I was searching for clinical trials about HPV and genital warts. I have learned that Panavir is very effective in combined therapy. It lowers recurrences of genital warts and increase the speed of HPV clearance.

I think that the best approach is combined therapy: Cryotherapy (or Podophyllotoxin) to remove genital warts, and Panavir gel to avoid recurrences.